ArriVent BioPharma Stock (NASDAQ:AVBP)

Forecast Ownership Financials Chart

Previous Close

$24.61

52W Range

$15.47 - $27.22

50D Avg

$22.43

200D Avg

$21.11

Market Cap

$1.07B

Avg Vol (3M)

$512.98K

Beta

1.00

Div Yield

AVBP Company Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jan 26, 2024

Website

AVBP Performance

AVBP Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	-	$-94.31M	$-74.59M
Net Income	$-166.31M	$-80.49M	$-69.33M
EBITDA	-	$-80.49M	$-74.59M
Basic EPS	$-4.32	$-2.56	$-2.17
Diluted EPS	$-4.32	$-2.56	$-2.17

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IOVA	Iovance Biotherapeutics, Inc.
DNA	Ginkgo Bioworks Holdings, Inc.
VALN	Valneva SE
MBX	MBX Biosciences, Inc. Common Stock
MGTX	MeiraGTx Holdings plc
DAWN	Day One Biopharmaceuticals, Inc.
ERAS	Erasca, Inc.
REPL	Replimune Group, Inc.
ARVN	Arvinas, Inc.